Welcome in CFDB (Cystic Fibrosis DataBase)!
This is a web-based, free access tool for health care professionals, researchers and students to evaluate in real time what are the current evidences about clinical efficacy of interventions in CF.
You'll find more than 1,300 studies divided in 8 sections, including Cochrane reviews, Cochrane protocols, DARE, HTA and Economic reviews, published RCT, published non-RCT, congress abstracts and ongoing trials.
Objective of CFDB (Cystic Fibrosis DataBase)
CFDB is a database and was ideated to classify clinical studies to get answers to specific questions:
- which interventions are effective, in which groups of CF patients and for which outcomes?
- to what extent do the results of the literature allow to make decisions for specific clinical issues? What issues need to be studied further?
This tool may help clinicians, researchers, students to have a faster updated view of clinical research in CF by using queries on the main topics in CF care. It could also be helpful to anyone going to design new studies, as it provides a concise description of what is currently known and what issues, on the contrast, need additional research.
Latest articles
CFTR modulator monotherapy for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)
Cochrane Database of Systematic Reviews - Cochrane Review
Details- 2026
- Matthew Heneghan
The Impact of Exercise Intervention on Pulmonary and Physical Function in Patients With Cystic Fibrosis: A Comprehensive Systematic Review.
Other Reviews - Other Review
Details- 2026
- Alghamdi A
Clinical effort against smoke exposure in cystic fibrosis (CEASE-CF): feasibility, acceptability, and preliminary efficacy.
primary studies published RCT
Details- 2026
- Oates GR
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study.
primary studies published RCT
Details- 2026
- Castellani C
Long-term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real-world cohort study.
primary studies published, non RCT
Details- 2026
- Perrotta N
Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy.
primary studies published, non RCT
Details- 2026
- Green N
AMBER: Azithromycin to Modify Bronchiectasis Exacerbation Risk - A Double-Blind Placebo-Controlled Randomized Trial in Adults With Non-Cystic Fibrosis Bronchiectasis - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2026
- Assiut University